Skip to main content
Premium Trial:

Request an Annual Quote

CIDR to Use Illumina Tech in Diabetes Research; Center Could Adapt Tech as Standard

NEW YORK, Jan. 11 (GenomeWeb News) - The Center for Inherited Disease Research will use Illumina's Sentrix HumanHap300 BeadChip and Infinium Assay for a pilot study of Type 2 diabetes, the company said today.

According to Illumina, one goal of the research is to evaluate its technology for possible adoption as the standard platform for CIDR's genome-wide association service, which is expected to launch in the spring.

Terms of the alliance call for CIDR to use the Sentrix HumanHap300 BeadChip to query more than 317,000 tagSNPs on a single microarray device. Specifically, CIDR is working with Illumina to genotype more than 2,500 case-control samples provided by the Finland-United States Investigation of NIDDM Genetics Study. Funded by the National Institutes of Health, the goal of the FUSION team is to map and identify genetic variants that predispose individuals to Type 2 diabetes.

Financial terms of the alliance were not disclosed.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.